Literature DB >> 2470455

Involvement of 5-HT2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analogue (CG 3509) to rats.

K C Fone1, J V Johnson, G W Bennett, C A Marsden.   

Abstract

1. The behavioural effects of the intrathecal injection of a thyrotrophin-releasing hormone (TRH) analogue L-orotyl-L-histidyl-prolineamide (CG 3509, 0.5 micrograms), the non-selective 5-HT1 and 5-HT2 receptor agonist 5-methoxy-N,N'-dimethyltryptamine (5-MeODMT, 2-100 micrograms) and the selective 5-HT2 receptor agonist 2,5-dimethoxy-alpha,4-dimethyl-benzene ethamine hydrochloride (DOM, 2-25 micrograms) were compared with the response of systemically administered 5-MeODMT (2 mg kg-1, i.p.) in rats, to establish whether the agonist-induced behaviours were mediated by bulbospinal 5-HT1 or 5-HT2 receptors. 2. Intrathecal injection of 5-MeODMT or DOM produced dose-related back muscle contractions (a previously undocumented behaviour) and wet-dog shakes which were both markedly attenuated by ritanserin pretreatment (1 mg kg-1, i.p.) indicating the involvement of 5-HT2 receptors. In contrast, reciprocal forepaw treading, flat body posture and Straub-tail were evoked by 5-MeODMT but not by DOM indicating that these behaviours were not produced by 5-HT2 receptor activation alone. However, as ritanserin pretreatment reduced the reciprocal forepaw treading induced by intrathecal 5-MeODMT, this behaviour may be facilitated by 5-HT2 receptor activation. 3. Intrathecal 5,7-dihydroxytryptamine (5,7-DHT, 2 x 150 micrograms) treatment decreased thoraco-lumbar spinal cord 5-HT (-95%) and potentiated the back muscle contractions produced by intrathecal DOM injection without altering the wet-dog shake behaviour. None of the components of the 5-HT syndrome produced by 5-MeODMT (2 mg kg-1, i.p.), with the exception of a small increase in wet-dog shakes, was significantly altered by intrathecal 5,7-DHT (which reduced thoraco-lumbar spinal cord 5-HT by 84%). Taken together these data suggest that the only 5-HT agonist-induced behaviour mediated by the activation of 5-HT2 receptors located postsynaptic to bulbospinal 5-hydroxytryptaminergic (5-HTergic) neurones was back muscle contractions. 4. The wet-dog shake and forepaw licking behaviors produced by intrathecal CG 3509 (0.5 micrograms) were attenuated when ritanserin was administered intrathecally 30 min before, but not when it was given at the same time as CG 3509 and neither behaviour was altered by intrathecal 5,7-DHT. This suggests that bulbospinal 5-HTergic neurones are not involved in the production of these TRH analogue-induced behaviours and that the 5-HT2 receptors which mediate these behaviours are not located in the spinal cord.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470455      PMCID: PMC1854385          DOI: 10.1111/j.1476-5381.1989.tb11858.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Substance P and 5-hydroxytryptamine immunoreactive presynaptic boutons on presumed alpha-motoneurons in the chicken ventral horn.

Authors:  S Atsumi; H Sakamoto; S Yokota; T Fujiwara
Journal:  Arch Histol Jpn       Date:  1985-04

2.  A comparison of the effects of serotonin, substance P and thyrotropin-releasing hormone on excitability of rat spinal motoneurons in vivo.

Authors:  S R White
Journal:  Brain Res       Date:  1985-05-27       Impact factor: 3.252

3.  Increased behavioural response to 5-methoxy-N,N-dimethyltryptamine but not to RU-24969 after intraventricular 5,7-dihydroxytryptamine administration.

Authors:  A P Nisbet; C A Marsden
Journal:  Eur J Pharmacol       Date:  1984-09-03       Impact factor: 4.432

4.  Early postnatal administration of 5,7-DHT: effects on serotonergic neurons and terminals.

Authors:  A C Towle; G R Breese; R A Mueller; S Coyle; J M Lauder
Journal:  Brain Res       Date:  1984-09-17       Impact factor: 3.252

5.  The distribution of thyrotropin-releasing hormone (TRH) in the rhesus monkey spinal cord.

Authors:  R M Lechan; S B Snapper; S Jacobson; I M Jackson
Journal:  Peptides       Date:  1984       Impact factor: 3.750

6.  The effects of lesions produced by 5,7-dihydroxytryptamine on 5-hydroxytryptamine-mediated behaviour induced by amphetamine in large doses in the rat.

Authors:  S L Dickinson; C D Andrews; G Curzon
Journal:  Neuropharmacology       Date:  1984-04       Impact factor: 5.250

7.  Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.

Authors:  I Lucki; M S Nobler; A Frazer
Journal:  J Pharmacol Exp Ther       Date:  1984-01       Impact factor: 4.030

8.  Intraventricular 5,7-dihydroxytryptamine increases thyrotropin-releasing hormone content in regions of rat brain.

Authors:  S Manaker; T M Engber; P B Knight; A Winokur
Journal:  J Neurochem       Date:  1985-10       Impact factor: 5.372

9.  Synergistic behavioral effects of serotonin and tryptamine injected intrathecally in mice.

Authors:  A A Larson; G L Wilcox
Journal:  Neuropharmacology       Date:  1984-12       Impact factor: 5.250

10.  Codepletion of serotonin and TRH induces apparent supersensitivity of spinal TRH receptors.

Authors:  N A Sharif; D R Burt; A C Towle; R A Mueller; G R Breese
Journal:  Eur J Pharmacol       Date:  1983-11-25       Impact factor: 4.432

View more
  12 in total

1.  The synthetic TRH analogue taltirelin exerts modality-specific antinociceptive effects via distinct descending monoaminergic systems.

Authors:  M Tanabe; Y Tokuda; K Takasu; K Ono; M Honda; H Ono
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

2.  Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN).

Authors:  Seth D Norrholm; Mahasweta Das; Gábor Légrádi
Journal:  Regul Pept       Date:  2005-05-15

3.  Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia.

Authors:  W Löscher; U Witte; G Fredow; M Ganter; K Bickhardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

4.  Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: Evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene.

Authors:  Anika Agarwal; Lisa M Halvorson; Gabor Legradi
Journal:  Brain Res Mol Brain Res       Date:  2005-07-29

5.  Influence of the 5-HT(2C) receptor antagonist SB242,084 on behaviour produced by the 5-HT(2) agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine.

Authors:  G A Higgins; A M Ouagazzal; A J Grottick
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

6.  Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin.

Authors:  U Freo; H W Holloway; N H Greig; T T Soncrant
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2013-02-14       Impact factor: 4.530

8.  Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting.

Authors:  Andrew P Ray; Seetha Chebolu; Juan Ramirez; Nissar A Darmani
Journal:  Behav Neurosci       Date:  2009-06       Impact factor: 1.912

9.  Age-related behavioural, neurochemical and radioligand binding changes in the central 5-HT system of Sprague-Dawley rats.

Authors:  L Robson; A J Gower; D A Kendall; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Effect of isolation rearing on 5-HT agonist-induced responses in the rat.

Authors:  I K Wright; H Ismail; N Upton; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.